Kardigan files for US IPO to fund heart drug development
Cardiovascular biotech Kardigan filed for a Nasdaq IPO to fund three late-stage therapies. The firm is developing precision medicines for heart diseases.
Xurve View
Insights:
Xurve View
Kardigan filed for an IPO in the United States to fund development of three late-stage cardiovascular therapies. The filing follows recent IPO moves by Parabilis Medicines and Oura amid a rebound in biotech issuance. Investors are returning to healthcare firms with clear paths toward commercialization.
